Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on October 11, 2018, regarding an event effective October 15, 2018. The filing pertains to Item 5.02, covering the appointment of a new senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is the appointment of Robert B. Ford as President and Chief Operating Officer, effective October 15, 2018. Mr. Ford, 45, previously served as Executive Vice President, Medical Devices since 2015. He has been with the company since 1996 and became a corporate officer in 2008.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the effective date of Robert B. Ford's appointment as President and COO (October 15, 2018).
- Confirm Mr. Ford's prior tenure and roles within Abbott Laboratories, specifically his leadership in Medical Devices and Diabetes Care.
- Review subsequent filings for any impact this leadership change may have on strategic direction or operational execution.